A medical monitor displaying vital signs with green waveforms on a dark screen
Jair Lázaro (Unsplash) / Unsplash License
Causes & What We Know/November 2, 2026/3 min read

How Doctors Monitor Teplizumab's Effect on Pancreatic Health: One Patient's Story

A case report shows how different glucose tests can track how teplizumab affects insulin production and blood sugar in the months after treatment. Understanding these monitoring tools may help doctors assess whether the therapy is slowing progression toward full Type 1 diabetes.

Research summaryPubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

causesautoimmunitygeneticsrisk

Key takeaways

  • Teplizumab is approved to delay progression from stage 2 to stage 3 Type 1 diabetes, but the best way to measure its effect early on is still being figured out
  • One 19-year-old patient showed normalized glucose tolerance 12 weeks after treatment and remained free of stage 3 diabetes 24 weeks later
  • Different tests—including oral glucose tolerance tests, mixed-meal tests, and continuous glucose monitoring—reveal different but complementary information about pancreatic function after teplizumab
  • This case suggests that tracking insulin production (C-peptide) and real-world blood sugar patterns, not just lab results, may be important for early monitoring

Understanding Stage 2 Type 1 Diabetes and Teplizumab

Type 1 diabetes develops in stages. In stage 2, a person has autoimmune markers (antibodies attacking the pancreas) and abnormal blood sugar on testing, but usually has no symptoms. Stage 3 is full-blown Type 1 diabetes, when the pancreas can no longer make enough insulin to keep blood sugar normal.

Teplizumab is a drug that received FDA approval specifically to slow or delay the move from stage 2 to stage 3. It works by modifying the immune system's attack on insulin-producing cells. In clinical trials, it has shown it can delay the onset of symptomatic diabetes, but questions remain about how best to monitor whether it's working in individual patients.

One Patient's Journey: Unmasking Hidden Autoimmunity

This case involves a 19-year-old woman who developed high blood sugar after taking strong corticosteroids (steroids used to treat other conditions). That hyperglycemia uncovered something hidden underneath: stage 2 Type 1 diabetes. Doctors confirmed it by finding multiple antibodies against pancreatic islet cells and by watching her glucose tolerance worsen over time—even though her pancreas was still producing insulin.

She received the standard 14-day course of intravenous teplizumab and then entered an intensive monitoring program to see how her pancreatic function changed.

What Three Different Tests Revealed After Treatment

After teplizumab, doctors used three complementary approaches to assess the patient's response:

An oral glucose tolerance test (OGTT)—where a person drinks a sugary liquid and blood sugar is measured—normalized by 12 weeks, meaning her body was handling glucose much better.

A mixed-meal tolerance test (MMTT), which mimics eating a real meal, showed that her pancreas was still producing C-peptide, a marker of functioning insulin-secreting cells. This suggested her insulin-making capacity was preserved.

Continuous glucose monitoring (CGM), a sensor worn on the skin that tracks blood sugar throughout the day and night, painted a real-world picture of her glucose patterns over 24 weeks without evidence of progression to stage 3 diabetes.

Why This Matters for Monitoring Strategies

This case cannot prove what the best monitoring strategy is—that would require many more patients and controlled comparisons. But it illustrates an important principle: no single test tells the whole story.

Lab tests like OGTT and MMTT show how the pancreas responds under controlled conditions. CGM shows what is actually happening in daily life, across sleep, meals, and activity. Together, they provide a more complete picture of whether teplizumab is working and whether the patient is progressing toward stage 3 diabetes.

As teplizumab becomes more widely available, establishing clear monitoring guidelines could help doctors and patients understand early on whether the treatment is slowing disease progression, and it may also help identify which tests matter most for follow-up care.

Evidence label

Source: Frontiers in endocrinology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

From Type1Cure

Read more of our own writing in Stories

More evidence-labeled coverage across the Type1Cure library.